Julie Kanter, MD, is associate professor, Division of Hematology and Oncology, director of the Adult Sickle Cell Disease Program, and codirector of the Comprehensive Sickle Cell Center at the University of Alabama at Birmingham. A lifespan hematologist specializing in sickle cell disease, Dr Kanter research is focused on access to care. Her focus include novel therapy development, sickle cell center development, implementation and dissemination of guideline-based SCD therapy and gene therapy. She works closely with national partners, including the American Society of Hematology, the Sickle Cell Disease Association of America, Inc, the Center for Disease Control, and the National Institutes of Health, on advocacy and research. She also works with industry and federal partners to develop new treatments for sickle cell disease. She has specific interests in gene therapy, anti-adhesion therapy, and novel combination therapy to treat sickle cell disease. Dr Kanter has received National Heart, Lung, and Blood Institute funding in dissemination and implementation to improve access to care for affected individuals. Dr Kanter has authored and coauthored more than 100 articles, book chapters, and abstracts. She hopes to train upcoming physicians and providers in sickle cell disease to expand the workforce for treating affected individuals.
Dr. Sophie Lanzkron is a Professor of Medicine and Oncology at Johns Hopkins University School of Medicine. Dr. Lanzkron is a hematologist and Director of the Sickle Cell Center for Adults. She received her BA from Brandeis University and she graduated from the Albert Einstein College of Medicine where she was inducted into the AOA honor society. She did her residency at the University of Maryland and her hematology fellowship at Hopkins. She is internationally recognized for her pioneering research on the optimal care and management of patients with sickle cell disease. She has served on the National Institutes of Health, Expert Panel in the Management of Sickle Cell Disease and on the American Society of Hematology’s Sickle Cell Guideline Panel. She is co-Chair of the Clinical Trial Sub-committee for the NIH’s Cure Sickle Cell Initiative and Chair of the American Society of Hematology’s Clinical Trial Network’s Patient Engagement Committee. Her research focus is on improving the quality of care provided to this historically underserved population and she is considered an expert in health services research in sickle cell disease. Dr. Lanzkron’s research is currently supported through grants from PCORI, the NIH and HRSA.
Dr. Deepa Manwani is the Director of the Hematology Program, Children’s Hospital at Montefiore (CHAM) and Professor of Pediatrics at Albert Einstein College of Medicine, Bronx, NY. Dr Manwani completed her residency (1993-96) at NSUH – Cornell University Medical College, NY. She received her sub specialty training in pediatric hematology – oncology (1996 - 99) at Mount Sinai School of Medicine. She conducted basic science research in the field of globin gene regulation, under the mentorship of Dr James Bieker, PhD at Mount Sinai School of Medicine from 1997-2006. Her primary areas of research focused on exploring mechanisms of fetal hemoglobin reactivation with the ultimate goal of designing novel therapies for sickle cell disease and thalassemia. She has also studied erythropoiesis and red cell-macrophage adhesive interactions in the erythroblast island. Her research interests focus on fetal hemoglobin activating agents, adhesive cellular interactions in vaso-occlusion in SCD and contribution of neutrophils to SCD pathophysiology. She completed the R01 funded Phase I Study of IVIG in treatment of SCD vaso-occlusive crises and is currently leading the R01 funded Phase II study. She has participated in NIH funded studies examining the modifiers of fetal hemoglobin expression. She has led quality improvement efforts that have led to significant reductions in readmission rates and length of stay for patients with SCD. She is currently participating in studies aimed at increased adherence to hydroxyurea and improved transition to adult care. She is also collaborating with investigators at Case Western Reserve University on a NHLBI R01 funded study to standardize monitoring of cellular adhesion in SCD patients using a novel microfluidic assay. Her contributions have been recognized by the Sickle Cell Thalassemia Patient Network of New York in the form of the “Distinguished Service Award” in March, 2015.
Marsha Treadwell, PhD, is a Professor of Psychiatry and Pediatrics at the University of California San Francisco. She is Jordan Fund Endowed Chair in the Department of Hematology/Oncology at UCSF Benioff Children’s Hospital Oakland. She is Co- PI and Regional Director for the HRSA funded Pacific Sickle Cell Regional Collaborative, that focuses on improving access to sickle cell disease care in 13 Western states. She is co-PI and Director for the Sickle Cell Care Coordination Initiative funded as a Sickle Cell Disease Implementation Consortium project by the National Heart, Lung and Blood Institute. The goal of the SCDIC is to use implementation science to improve outcomes for adolescents and adults with sickle cell disease by improving understanding of barriers to care and utilization of evidence-based guidelines. Dr. Treadwell is recognized internationally as an expert in the transition from pediatric to adult care, quality of life, patient reported outcomes and community engagement. Dr. Treadwell’s service includes the NHLBI Sickle Cell Disease Advisory Committee, Cure Sickle Cell Initiative Clinical Trials and Outcomes workgroups and the consensus measures for Phenotypes and eXposures (PhenX) Sickle Cell Disease Scientific and Research Panel. Dr. Treadwell is committed to dismantling the structures that underlie sickle cell disease health disparities, including by mentoring individuals from groups underrepresented in medicine at all levels, from high school through faculty.